Company profile: BioNxt
1.1 - Company Overview
Company description
- Provider of precision transdermal and oral drug formulations for neurological disorders; point-of-care diagnostics for infectious diseases (COVID-19, H1N1, H5N1), including a rapid COVID-19 PCR test; production, formulation, and validation of new APIs; industrial-scale production and clinical validation of psychedelic compounds for mental health treatments, including addiction and depression.
Products and services
- Precision Transdermal and Oral Drug Formulations: BioNxt develops precision-engineered transdermal and oral drug formulations to improve patient outcomes for neurological disorders, concentrating on delivery modalities that improve outcomes
- Production and Formulation of New APIs: BioNxt produces, formulates, and validates new active pharmaceutical ingredients for various medical applications, executing validation-focused API programs from initial production through formulation and verification
- Psychedelic Production: BioNxt develops industrial-scale production methods for pharmaceutical-grade psychedelic compounds for mental health treatments, establishing scalable manufacturing approaches for psychiatric applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioNxt
Virpax Pharmaceuticals
HQ: United States
Website
- Description: Provider of intranasal and topical therapeutics for pain, epilepsy, and viral inhibition, including: Probudur, a single-injection liposomal bupivacaine for extended post-operative pain; Envelta, intranasal enkephalin for acute/chronic and cancer pain; NobrXiol, intranasal CBD for rare pediatric epilepsy; AnQlar, intranasal spray to inhibit influenza/SARS-CoV-2; and Epoladerm, topical diclofenac spray film for osteoarthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Virpax Pharmaceuticals company profile →
Sensile Medical
HQ: Switzerland
Website
- Description: Provider of liquid drug delivery devices and platforms developed in Switzerland, offering safe, cost-efficient, customizable on- and off-body solutions—featuring reusable and disposable concepts—for subcutaneous administration of biologics and small molecules, including Gx SensAir, on-body and belt-worn infusors with adjustable flow and connectivity, an inhalation assessment platform, and the Gx Inbeneo autoinjector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensile Medical company profile →
Aquarius Bio
HQ: United States
Website
- Description: Provider of a proprietary drug delivery platform to improve existing drugs, specializing in biotechnology, medicine, and pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquarius Bio company profile →
Cellics Therapeutics
HQ: United States
Website
- Description: Provider of biomimetic nanomedicines based on cellular nanosponges—nanoparticles coated with cell membranes—to bind and neutralize bacterial toxins, cytokines, and viruses. Products include CTI-005, a red blood cell nanosponge for MRSA pneumonia, and CTI-111, a macrophage nanosponge for sepsis that absorbs and neutralizes toxins and inflammatory cytokines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellics Therapeutics company profile →
Mipharm
HQ: Italy
Website
- Description: Provider of pharmaceutical manufacturing across oral solids, oral liquids, nasal sprays, semi-solids, and suppositories; customized and secure packaging; research and development for new formulations and optimization of existing ones; clinical trial logistics; and formulation development and production of experimental drugs for clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mipharm company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioNxt
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioNxt
2.2 - Growth funds investing in similar companies to BioNxt
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioNxt
4.2 - Public trading comparable groups for BioNxt
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →